Search This Blog

Monday, August 10, 2026

AirSculpt misses, cuts guidance

 

AirSculpt Technologies misses Q2 estimates with EPS $0.01, revenue $42.9M, cuts full-year adjusted EBITDA guidance to $12–$14M

  • Non-GAAP EPS $0.01 declined 50% year over year in fiscal Q2 2026.
  • Revenue $42.9M decreased 3% year over year in fiscal Q2 2026.
  • Company reported $1.1M net loss for fiscal Q2 2026 period.

Axsome Q2 2026 revenue rises 44%, EPS misses, FDA accepts AXS-12 narcolepsy NDA

 

Axsome Q2 2026 revenue rises 44% to $216.4M as EPS -$0.99 misses estimates and FDA accepts AXS-12 narcolepsy NDA

  • Non-GAAP EPS was -$0.99 in Q2 2026, down 2% year over year.
  • Q2 2026 revenue of $216.4M increased 44% YoY, below the $224.5M analyst revenue estimate.

MoonLake beats Q2 2026 EPS estimates, positive Phase 3 IZAR-1 psoriatic arthritis results

 

MoonLake beats Q2 2026 EPS estimates with non-GAAP EPS -0.84 and posts positive Phase 3 IZAR-1 psoriatic arthritis results

  • Non-GAAP EPS was -0.84 in Q2 2026, improving 3% year-over-year.
  • Q2 2026 revenue was $0, beating revenue estimates despite no reported product revenue.
  • Positive Phase 3 IZAR-1 results were achieved in biologic-naïve patients with psoriatic arthritis.

Kalshi Taps Nasdaq Surveillance Tech as Prediction Markets Face Insider Trading Scrutiny

 Prediction markets operator Kalshi on Monday said it has partnered with Nasdaq (NASDAQ:NDAQ) to deploy the exchange operator's market surveillance technology, seeking to strengthen oversight of trading activity on its platform.

The multi-year partnership comes as prediction markets face growing scrutiny from lawmakers and regulators following high-profile allegations of insider trading and market manipulation.

Kalshi said it will implement Nasdaq's surveillance platform in phases, combining its existing monitoring systems with enhanced capabilities designed for prediction markets and perpetual-style derivatives. The technology will provide round-the-clock monitoring to help detect potential market abuse, manipulation and insider trading in real time.

The integration will also support Kalshi in providing trading data to the Commodity Futures Trading Commission in the format required by the regulator, the companies said.

The CFTC last month fined former Republican Representative George Santos $35,000 over alleged manipulative trading on Kalshi. A White House teleprompter operator is also under investigation for potential insider trading on the platform, Reuters reported.

https://finance.yahoo.com/markets/options/articles/kalshi-taps-nasdaq-surveillance-tech-124335644.html

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 m upfront plus up to $500 m in milestones

 


  • Deal adds Actio's lead rare epilepsy candidate ABS-1230 to Jazz's neurology and epilepsy portfolio.

Quanterix cuts 2026 revenue and margin outlook, delays cash-flow breakeven

 

Quanterix cuts 2026 revenue and margin outlook, delays cash-flow breakeven to 2027 after Q2 results miss EPS and revenue estimates with EPS -$1.04, revenue $32.9M

  • Q2 non-GAAP EPS declined 35% year over year to -$1.04
  • Q2 revenue rose 34% year over year to $32.9M

Tenax Therapeutics' Phase 3 LEVEL trial of TNX-103 in PH-HFpEF fails primary, key secondary endpoints


  • Company will seek a Type C FDA meeting to revise TNX-103 registrational development plan after trial failure.